Hypolipidemics Global Market Report 2021 Featuring Abbott Laboratories, Apotex Fermentation, Biocon, Cadila Healthcare and Chunghwa Chem Syn & Biotech


DUBLIN, December 02, 2021 - (BUSINESS WIRE) - The report "Hypolipidemis Global Market Report 2021: COVID-19 Impact and Recovery to 2030" has been added ResearchAndMarkets.com to offer.

The global hypolipidemia market is forecast to decline from $ 16.23 billion in 2020 to $ 15.94 billion in 2021, with an average annual growth rate (CAGR) of -1.8%.

The decline is mainly due to the fact that companies' production was negatively impacted by COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of commercial activities that created operational challenges.

The market is expected to reach $ 18.41 billion in 2025 at a CAGR of 3.7%.

Key players in the Hypolipidemic Drugs market are Abbott Laboratories Ltd, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited, and Chunghwa Chem Syn & Biotech Co., Ltd.

Hypolipidemic Drugs market consists of hypolipidemic drug sales and related services. This industry includes facilities that manufacture hypolipidemic drugs or agents that lower lipid and lipoprotein levels in the blood. These drugs can be used to prevent cardiovascular disease and atherosclerosis in patients with hyperlipidemia. Some of the major hypolipidemic drugs include fibric acid derivatives, bile acid binding resins, nicotinamides, and cholesterol absorption inhibitors.

The market treated by this report is segmented by product type into Cholic Acid Regulator, HMG-CoA Reductase Inhibitor, Adenylate Cyclase Inhibitor, Nicotinic Acid Drugs, and others; by application in hospitals, clinics, pharmacies, cardiovasology.

Changes in people's diet and lifestyle are driving the growth of the hypolipidemic drug market. The increase in the consumption of unhealthy foods, the increasing prevalence of smoking and drinking have all led to an increase in the cholesterol intake of the population. High blood pressure contributed to nearly 1.47 million deaths in India, according to a 2019 study by Global Burden of Disease (GBD). The rise in cholesterol due to the change in people's lifestyle increases the demand for hypolipidemic drugs as they help in lowering cholesterol.

The story goes on

Companies in this market are increasingly investing in the use of data from wearables in clinical studies in order to improve the speed and efficiency of studies and thereby reduce overall costs. By continuously collecting patient data through wearable technologies, clinical trial sponsors can potentially reduce the burden of frequent site visits, which could improve patient dropout rates and the overall efficiency of clinical trials.

The use of wearables helps meet the challenge of patient recruitment, helps monitor patients, provides accurate real-time data and enables earlier decisions while the patient is in a clinical trial. Pharmaceutical companies like Sanofi and Pfizer have already invested in wearable technologies to treat hypolipidemia.

The increase in the use of biologicals acts as a major obstacle hindering the growth of the hypolipidemic drug market. Biologics are obtained from living organisms such as humans, animals and microorganisms, as opposed to chemical drugs or chemically synthesized drugs.

The increasing preference for hypolipidemic biological drugs due to side effects in the use of chemically synthesized drugs has resulted in a decline in sales of traditional hypolipidemic chemical drugs and thus hinders the growth of the hypolipidemic (chemical) drug market.

According to Harvard Medical School, 10 to 29% of people who consume hypolipidemic drugs, such as cholesterol-lowering statins, experience muscle aches and pains. For example, PCSK9 inhibitors have been used since 2015 to lower LDL cholesterol. Amgens' Repatha, a hypolipidemic biological drug, has received FDA approval for the treatment of hypolipidemia.

The approval of the hypolipidemic drugs by the EU authorities takes 6 to 12 months. Additionally, all parts of the registration dossier must be submitted together, unlike the US FDA which accepts phased filings. The US FDA will evaluate each technical section in 6 months, which can be extended to an additional 6 months if questions / concerns are raised.

However, the assessment of the technical sections is done at the same time and therefore manufacturers should identify the time-consuming steps and plan the work accordingly and indicate an anticipated approval date. In addition, the validity of the license and the extension of the application in the EU region place a burden on the manufacturer and increase the existing regulatory burden.

Therefore, hypolipidemia drug manufacturers should plan well and communicate effectively in order to minimize costs and shorten lead times.

Key topics covered:

1. Summary

2. Market characteristics for hypolipidemic drugs

3. Hypolipidemic Drugs Market Trends and Strategies

4. Effects of COVID-19 on Hypolipidemic Drugs

5. Hypolipidemia Drugs Market Size and Growth

5.1. Global Historic Hypolipidemic Drugs Market, 2015-2020, $ Billion

5.1.1. Driver of the market

5.1.2. Restrictions in the market

5.2. Global Hypolipidemic Drugs Prediction Market, 2020-2025F, 2030F, Billion US Dollars

5.2.1. Driver of the market

5.2.2. Restrictions in the market

6. Hypolipidemic Drugs Market Segmentation

6.1. Global Hypolipidemic Drugs Market, Segmentation by Product Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

6.2. Global Hypolipidemic Drugs Market, Segmentation By Application, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

  • hospital

  • Clinics

  • pharmacy

  • Cardiovasology

7. Regional and country analysis of the market for hypolipidemic drugs

7.1. Global Hypolipidemic Drugs Market Split by Region, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

7.2. Global Hypolipidemic Drugs Market Split by Country, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

Mentioned companies

  • Abbott Laboratories Limited

  • Apotex Fermentation Inc.

  • Biocon Limited

  • Cadila Healthcare Limited

  • Chunghwa Chem Syn & Biotech Co. GmbH.

  • Concord Biotech Limited

  • Croda Europe Limited Leeks

  • Daiichi Sankyo Company Limited

  • Dr. Reddy's Laboratories Ltd

  • DSM Sinochem Pharma India

  • Hikal

  • Ipca laboratories

  • Lek Pharmaceuticals dd

  • Lupine Limited

  • Merck Sharp & Dohme BV

  • Mylan NV

  • Nexchem Pharmaceutical Co. Ltd. CN

  • Olon SpA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Zhejiang Jiangbei Pharma Co. Ltd. CN.

  • Moehs Iberica SL ES

  • Pfizer Inc

  • Recordati SpA IT Milano

  • AstraZeneca

  • Amgen

  • Daiichi Sankyo

  • Kowa Company Ltd.

  • Sanofi

  • Novartis

Please visit https://www.researchandmarkets.com/r/rtjik0 for more information on this report

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005532/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For EST office hours, call 1-917-300-0470
For US / CAN toll free call 1-800-526-8630
For GMT office hours, call + 353-1-416-8900. at


continue reading https://dailytechnonewsllc.com/hypolipidemics-global-market-report-2021-featuring-abbott-laboratories-apotex-fermentation-biocon-cadila-healthcare-and-chunghwa-chem-syn-biotech/?feed_id=3121&_unique_id=61b75bd423266

Commentaires

Enregistrer un commentaire

Posts les plus consultés de ce blog

Projections for the gambling industry for 2022

Image
W. ith 2021, which is almost behind us, it is time to look ahead to 2022. While it will be a few more months, most business people are already planning strategies for what lies ahead. These were exciting years with many unpredictable events and trends. We have seen how digital currencies, virtual reality, esports, live dealer games, IoT and many other technologies have found their place in the industry. The importance of cell phones to the gambling industry has also been shown. What else have the last two years taught us and what can we expect from the next year? The year that everything changed 2020 was a year neither of us was prepared for. Due to the COVID-19 pandemic, the world was closed until mid-March, sporting events were canceled and land casinos closed. The operators were preparing for a difficult time,
Lire la suite

Tremendous scope for India-US cooperation in health technology and pharma, says expert

Image
As the US government stepped up its support to India in its fight against a deadly wave of COVID-19, an Indian public health expert pointed out the enormous scope for collaboration between India and the US on health technology and pharmaceuticals. "Now that we are out of the crisis, health technology and pharmaceuticals are two areas where there is tremendous scope for India-US collaboration," said Indian official Dr. Mrinalini Darswal, who is currently doing a PhD in public health with a focus on COVID-19 at Harvard University, tells. Darswal, a 2002 IAS officer for Odisha cadres, said India had demonstrated its expertise in the health sector, particularly in terms of speed of innovation, manufacturing and cost efficiency. It would be beneficial for the US to leverage India's technical expertise and installed drug manufacturing capabilities to source healthcare equipment, drugs, personal protective equipment and vaccines now at competitive prices, she said. "
Lire la suite

Global Home Sleep Screening Wearable Devices Market Insights Report, Forecast to 2027 – KSU

Image
This latest report on Portable Home Sleep Screening Devices published by Global Market Monitor covers current market dynamics, and offers effective competitive strategies and market guidelines for the majority of practitioners. Get a sample copy of the Wearable Home Sleep Screening Devices Market report at: https://www.globalmarketmonitor.com/request.php?type=1&rid=655284 Main manufacture: To gain an insight into the competitive landscape, the report provides an overview of the major players in the Portable Devices for Home Sleep Screening Market including: ResMed VirtuOx Itamar Medical Royal Philips SleepWorks Cleveland Medical Devices Responsive surface technology Huawei Fitbit This is sleep dreams Garmin Huami ApnoeMed Simmons Bedding Company NovaSom Fossil group Take a look at the comprehensive analysis on different segments: https://www.globalmarketmonitor.com/reports/655284-home-sleep-screening-wearable-devices-market-report.html Home Sleep Screening Wearable
Lire la suite